Purpose: Numerous studies have examined non-adherence to adjuvant endocrine therapy in women recovering from breast cancer, but none provide a comprehensive theory to explain the challenges of long-term medication-taking and resilience needed to continue. The aim of this study was to source, appraise, and synthesise data from existing qualitative studies to develop an in-depth explanatory model of non-adherence and discontinuation of hormonal medication among breast cancer survivors. Methods: A comprehensive search of databases and the literature identified 24 eligible qualitative studies published 2010-2019. Quotations (n= 801) listed within these papers and the original author interpretations were synthesised using NVivo, and grounded th...
Background: Adjuvant endocrine therapy (AET) significantly decreases the risk of br...
An additional 5 years of treatment with adjuvant hormonal therapy, to complete 10 years of medicatio...
This study evaluates compliance and persistence in adjuvant endocrine breast cancer (BC) therapy by ...
Purpose: A literature review and meta-synthesis of qualitative research had enabled us to develop a ...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast ca...
Objective: To explore women’s experiences of taking adjuvant endocrine therapy as a treatment for br...
Jo Brett,1 Mary Boulton,1 Debbie Fenlon,2 Nick J Hulbert-Williams,3 Fiona M Walter,4 Peter Donnelly,...
Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortal...
An additional 5 years of treatment with adjuvant hormonal therapy, to complete 10 years of medicatio...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Objective: To explore women's experiences of taking adjuvant endocrine therapy as a treatment for br...
Adjuvant endocrine therapy (ET) can reduce the risk of recurrence among females with hormone recepto...
Background: Adjuvant endocrine therapy (AET) significantly decreases the risk of br...
An additional 5 years of treatment with adjuvant hormonal therapy, to complete 10 years of medicatio...
This study evaluates compliance and persistence in adjuvant endocrine breast cancer (BC) therapy by ...
Purpose: A literature review and meta-synthesis of qualitative research had enabled us to develop a ...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast ca...
Objective: To explore women’s experiences of taking adjuvant endocrine therapy as a treatment for br...
Jo Brett,1 Mary Boulton,1 Debbie Fenlon,2 Nick J Hulbert-Williams,3 Fiona M Walter,4 Peter Donnelly,...
Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortal...
An additional 5 years of treatment with adjuvant hormonal therapy, to complete 10 years of medicatio...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Objective: To explore women's experiences of taking adjuvant endocrine therapy as a treatment for br...
Adjuvant endocrine therapy (ET) can reduce the risk of recurrence among females with hormone recepto...
Background: Adjuvant endocrine therapy (AET) significantly decreases the risk of br...
An additional 5 years of treatment with adjuvant hormonal therapy, to complete 10 years of medicatio...
This study evaluates compliance and persistence in adjuvant endocrine breast cancer (BC) therapy by ...